Saltigo GmbH is continuing the development of its pharmaceutical business portfolio. The wholly owned LANXESS subsidiary signed in Tokyo an agreement with Daiichi Sankyo Co., Ltd. for the provision of contract manufacturing services. These are associated with the preparation for commercialization of one of Daiichi Sankyo’s novel drug pipeline projects. A corresponding signing ceremony took place in Tokyo.
Schmitz comments: “Daiichi Sankyo is one of the largest pharma players in the second largest pharma market in the world and decided to work with a globally recognized CMO-partner such as our company. So, it is a great honor for Saltigo to enter into this agreement with Daiichi Sankyo and we look forward to the continuation and further proactive development of our business relationship.”